



(51) International Patent Classification:

A61K 31/69 (2006.01) A61P 31/04 (2006.01)
C07F 5/02 (2006.01)

(21) International Application Number:

PCT/US2011/050728

(22) International Filing Date:

7 September 2011 (07.09.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/380,596 7 September 2010 (07.09.2010) US

(71) Applicant (for all designated States except US): ANACOR PHARMACEUTICALS, INC. [US/US]; 1020 East Meadow Circle, Palo Alto, CA 94303 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HERNANDEZ, Vincent, S.** [US/US]; 287 Gilchrist Lane, Watsonville, CA 95076 (US). **DING, Charles** [US/US]; 23 Treetop Lane, San Mateo, CA 94402 (US). **PLATTNER, Jacob, J.** [US/US]; 119 Via Floreado, Orinda, CA 94563 (US). **ALLEY, Michael Richard, Kevin** [GB/US]; 3751 Lillick Drive, Santa Clara, CA 95051 (US). **ROCK, Fernando** [US/US]; 1183 Lisa Lane, Los Altos, CA 94024 (US). **ZHANG, Suoming** [CN/US]; 3702 Redwood Circle, Palo Alto, CA 94306 (US). **EASOM, Eric** [US/US]; 1558 Mercy Street, Mountain View, CA 94041 (US). **LI, Xianfeng** [CA/US]; 10059 Craft Drive, Cupertino, CA 95014 (US). **ZHOU, Ding** [CN/CN]; 2nd Floor, Bldg. 1B, 528 Rui Qing Road, Shanghai, Pudong 201201 (CN).

(74) Agent: **ESKER, Todd**; Morgan, Lewis & Bockius, LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))


(88) Date of publication of the international search report:

10 May 2012


(54) Title: BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS



(I)



(II)



(III)

(57) Abstract: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections. The compounds are of formula (I), (II) or (III) wherein R³ is substituted or unsubstituted nitroalkyl or substituted or unsubstituted aminoalkyl; R⁴ is selected from the group consisting of halogen, unsubstituted alkyl, unsubstituted alkoxy, and unsubstituted phenyl; Y is O or S; and R⁵ is selected from the group consisting of substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; or a salt, hydrate or solvate thereof.